BackgroundData from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) were used previously to develop a risk score calculator to predict 1-year survival. We evaluated prognostic implications of changes in the risk score and individual risk-score parameters over 12 months.MethodsPatients were grouped by decreased, unchanged, or increased risk score from enrollment to 12 months. Kaplan-Meier estimates of subsequent 1-year survival were made based on change in the risk score during the initial 12 months of follow-up. Cox regression was used for multivariable analysis.ResultsOf 2,529 patients in the analysis cohort, the risk score was decreased in 800, unchanged in 959, and increased in 770...
International audienceIntroduction Contemporary risk assessment tools categorise patients with pulmo...
Background: In patients with pulmonary arterial hypertension (PAH), risk stratification is used to...
BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of ...
BackgroundData from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Dis...
The European Society of Cardiology (ESC) and European Respiratory Society (ERS) guideline recommenda...
BACKGROUND: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the nonin...
Abstract Background Risk assessment of pulmonary arterial hypertension (PAH) contributes to its mana...
BACKGROUND: The multinational AMBITION study demonstrated a 50% risk reduction in time to first clin...
Abstract Risk stratification is an essential tool in the management of pulmonary arterial hypertensi...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
BACKGROUND: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) ...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
Background: Risk stratification plays an essential role in the management of patients with pulmonary...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
Aims: Low‐risk status in pulmonary arterial hypertension (PAH) predicts better survival. The present...
International audienceIntroduction Contemporary risk assessment tools categorise patients with pulmo...
Background: In patients with pulmonary arterial hypertension (PAH), risk stratification is used to...
BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of ...
BackgroundData from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Dis...
The European Society of Cardiology (ESC) and European Respiratory Society (ERS) guideline recommenda...
BACKGROUND: Approaches to risk assessment in pulmonary arterial hypertension (PAH) include the nonin...
Abstract Background Risk assessment of pulmonary arterial hypertension (PAH) contributes to its mana...
BACKGROUND: The multinational AMBITION study demonstrated a 50% risk reduction in time to first clin...
Abstract Risk stratification is an essential tool in the management of pulmonary arterial hypertensi...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
BACKGROUND: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) ...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
Background: Risk stratification plays an essential role in the management of patients with pulmonary...
BACKGROUND: Risk stratification plays an essential role in the management of patients with pulmonary...
Aims: Low‐risk status in pulmonary arterial hypertension (PAH) predicts better survival. The present...
International audienceIntroduction Contemporary risk assessment tools categorise patients with pulmo...
Background: In patients with pulmonary arterial hypertension (PAH), risk stratification is used to...
BACKGROUND: The prognostic value of improvement endpoints that have been used in clinical trials of ...